Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study)
OPEN Neurologia (Barcelona, Spain) | 23 Jul 2013
R Díez Valle, J Slof, J Galván, C Arza, C Romariz and C Vidal
To assess effectiveness of 5-aminolevulinic acid (5-ALA, Gliolan(®)) in patients treated for malignant glioma under typical daily practice conditions in Spain, using complete resection rate (CR) and progression free survival at 6 months (PFS6).
* Data courtesy of Altmetric.com